The proposed Operation is part of the strategic transformation project between TheraVet and H4 Orphan Pharma aimed at developing the H4 Orphan Pharma’s flagship clinical program in idiopathic pulmonary fibrosis and capitalizing on TheraVet teams to accelerate its development by leveraging its regulatory advances in Belgium.